Tenofovir Disoproxil Fumarate: New Chemical Developments and Encouraging in vitro Biological Results for SARS-CoV-2

• Autor(a) principal: Clososki,Giuliano C.
• Data de Publicação: 2020
• Outros Autores: Soldi,Rafael A., Silva,Rodrigo M. da, Guaratini,Thais, Lopes,José N. C., Pereira,Pâmela R. R., Lopes,João L. C., Santos,Thiago dos, Martins,Ronaldo B., Costa,Cristina S., Carvalho,Andréia N. de, da Silva,Luis L. P., Arruda,Eurico, Lopes,Norberto P.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Journal of the Brazilian Chemical Society (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532020000801552
• topic: tenofovir disoproxil fumarate; scale-up studies; putative metabolites; SARS-CoV-2; COVID-19; infrared spectroscopy; electrospray ionization mass spectrometry

The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led society to live with a serious public health problem. In this sense, repositioning of antiretrovirals has captured the attention of the scientific community. Tenofovir disoproxil fumarate (TDF) is an antiretroviral compound that is used to treat acquired immune deficiency syndrome (AIDS) and hepatitis B. In this short report, we present a scale-up investigation of TDF by in situ infrared spectroscopy monitoring and a forced degradation study to describe a new degradation product. Finally, we have evaluated TDF in vitro for SARS-CoV-2 for the first time foreseeing the using of this medicine in pre-clinical and clinical investigations for the COVID-19 (coronavirus disease 2019) treatment.